Vulvovaginal candidiasis
Drug research and approvals for vulvovaginal candidiasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 11 studies of vulvovaginal candidiasis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 11
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal CandidiasisNCT07603895 · Not applicable · Bioithas SL · starts May 25, 2026
- Biweekly Long-term Occidiofungin Study for Suppression of Mycotic RecurrenceNCT07521137 · Phase 2 · Sano Chemicals Inc · starts Jun 4, 2026
- Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial VaginosisNCT07234786 · Not applicable · Karo Pharma AB · starts Oct 22, 2025
- Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)NCT06983041 · Not applicable · Coologics, Inc · starts May 22, 2025
- Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with…NCT06835361 · Phase 2 / Phase 3 · AVVA Pharmaceuticals Ltd. · starts Feb 29, 2024
- A Study of the Efficacy and Safety of WXSH0102 in Treating VCC PatientsNCT06771063 · Phase 2 · Cisen Pharmaceutical CO., LTD. · starts Jan 13, 2025
- Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal CandidiasisNCT06480604 · Not applicable · The Archer-Daniels-Midland Company · starts Oct 15, 2024
- Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant OutcomesNCT05908682 · Not reported · GlaxoSmithKline · starts Nov 12, 2025
- Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal MicrobiomeNCT05753813 · Early Phase 1 · Queen's Medical Center · starts Dec 15, 2023
Approved 3
- FluconazoleCytochrome P450 51 inhibitor
- OteseconazoleLanosterol 14-alpha demethylase inhibitor
- Ibrexafungerp1,3-beta-glucan synthase inhibitor
Phase 3 6
- ClotrimazoleCytochrome P450 51 inhibitor
- KetoconazoleCytochrome P450 51 inhibitor
- Boric acid
- Amphotericin bErgosterol sequestering agent
- TerconazoleCytochrome P450 51 inhibitor
- TetracyclineBacterial 70S ribosome inhibitor
Phase 2 6
- ChlorhexidineCell membrane inhibitor
- MiconazoleCytochrome P450 51 inhibitor
- SertaconazoleCytochrome P450 51 inhibitor
- ButoconazoleCytochrome P450 51 inhibitor
- Arasertaconazole
- Domiphen
How its trials ended
93 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 63% met their primary endpoint, 0% missed it and 37% stopped early.
- Completed, result not reported4447%
- Ongoing1516%
- Status unknown1516%
- Met its primary endpoint1213%
- Stopped: other or unclear55%
- Stopped: enrollment or feasibility22%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Sep 12, 2018 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of VT-1161 oral capsules in the treatment of subjects with…Oteseconazole (VT-1161)/ Fluconazole | Mycovia Pharmaceuticals | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA